CRC Research Update — August 18, 2026
Today's colorectal cancer research highlights
egfr
A collection of 27 issues
Meta-analysis compares EGFR inhibitors versus bevacizumab for converting unresectable liver metastases
Skip to content
The CRC Digest
▸ TREATMENT
Meta-analysis compares EGFR inhibitors versus bevacizumab for converting unresectable liver metastases
A systematic review and meta-analysis of randomized trials in patients with RAS wild-type colorectal liver metastases compared chemotherapy combined with EGFR inhibitors versus bevacizumab as first-line treatment, analyzing data from 795 patients
CRC Research Update — July 28, 2026
Today's colorectal cancer research highlights
Review Examines Resistance Mechanisms to Anti-EGFR Therapies
Skip to content
The CRC Digest
Review Examines Resistance Mechanisms to Anti-EGFR Therapies
A review of cetuximab and panitumumab resistance found that intrinsic resistance often stems from pre-existing KRAS, NRAS, and BRAF mutations, while acquired resistance develops through clonal evolution under therapeutic pressure. (Pharmaceuticals)
This content is informational only and
CRC Research Update — July 27, 2026
Today's colorectal cancer research highlights
Cetuximab Rechallenge Tested Against Regorafenib in RAS Wild-Type mCRC
Skip to content
The CRC Digest
◆ TRIAL DATA
Cetuximab Rechallenge Tested Against Regorafenib in RAS Wild-Type mCRC
A single-center randomized trial evaluated cetuximab plus irinotecan rechallenge versus regorafenib in RAS wild-type, microsatellite-stable metastatic colorectal cancer patients who had previously responded to then progressed off cetuximab, with progression-free survival as the
CRC Research Update — July 01, 2026
Today's colorectal cancer research highlights
CRC Research Finding
Skip to content
The CRC Digest
▸ Multi-omics deep learning model predicts anti-EGFR therapy response in liver metastases
A multi-center study developed a deep learning framework integrating multi-omics data to predict which RAS wild-type colorectal cancer liver metastases patients will benefit from cetuximab therapy, addressing primary resistance challenges. (Curr Cancer Drug
CRC Research Update — June 27, 2026
Today's colorectal cancer research highlights
CRC Research Update — June 19, 2026
Today's colorectal cancer research highlights